VNDRIQ — Vendor Comparison
Manchester Imaging vs CellmatiQ
Side-by-side comparison of BAA status, PHI exposure, AI training risk, HIPAA suitability, and VNDRIQ governance scores.
Manchester Imaging
Dental Imaging AI
Verification pending
CellmatiQ
Dental Imaging AI
Verification pending
VNDRIQ Scores
47
Overall
35
Overall
Approval Tier
BAA Status
PHI Exposure Risk
AI Training Risk
HIPAA Risk Level
Review Frequency
Quarterly
Quarterly
Recommended Use
AI-assisted detection of enamel-only proximal caries and osteoporosis risk assessment (OsteoDent) from dental X-rays.
Automated cephalometric landmark identification and diagnostic support for dental pathologies in clinical settings.
Restrictions
Primarily marketed in the UK and used in university dental schools; US clinical use requires verification of FDA 510(k) clearance which is not explicitly documented in current search results.
Primarily certified for the EU market (CE mark); FDA clearance for the US market is not confirmed in available documentation.
Executive Summary
Manchester Imaging
Dental Imaging AI
Manchester Imaging is classified as Conditional / Verify BAA with a BAA status of Not explicitly stated; the company is based in the UK and emphasizes GDPR compliance and ISO-13485 standards for medical devices.. PHI exposure is rated High and AI training risk is Medium. AI-assisted detection of enamel-only proximal caries and osteoporosis risk assessment (OsteoDent) from dental X-rays.
36
Privacy
55
Governance
42
Healthcare
55
AI Risk
CellmatiQ
Dental Imaging AI
CellmatiQ is classified as Restricted / Review Required with a BAA status of No public Business Associate Agreement (BAA) was identified in the search results; the company primarily emphasizes EU CE certification and GDPR compliance.. PHI exposure is rated High and AI training risk is High. Automated cephalometric landmark identification and diagnostic support for dental pathologies in clinical settings.
36
Privacy
37
Governance
35
Healthcare
30
AI Risk
Recommended For
Manchester Imaging
AI-assisted detection of enamel-only proximal caries and osteoporosis risk assessment (OsteoDent) from dental X-rays.
Organizations able to execute BAA prior to deployment
IT teams with capacity to verify data handling agreements
CellmatiQ
Automated cephalometric landmark identification and diagnostic support for dental pathologies in clinical settings.
Currently under review — not recommended for active PHI deployment
Governance Considerations
Manchester Imaging
PHI exposure is elevated. Review data flow documentation.
Quarterly reviews are required — establish internal review cadence.
Restrictions noted: Primarily marketed in the UK and used in university dental schools; US clinical use requires verification of FDA 510(k) clearance which is not explicitly documented in current search results.
CellmatiQ
Verify model training opt-out clauses before deployment.
PHI exposure is elevated. Review data flow documentation.
Quarterly reviews are required — establish internal review cadence.
Restrictions noted: Primarily certified for the EU market (CE mark); FDA clearance for the US market is not confirmed in available documentation.
Questions to Ask Before Approval
Has the vendor executed a Business Associate Agreement (BAA) with your organization?
Does the vendor use customer data to train AI models? Can you opt out?
Where is PHI stored, processed, and transmitted?
What data retention and deletion policies apply to your PHI?
Has the vendor undergone a third-party HIPAA or SOC 2 audit?
What is the vendor's incident response and breach notification process?
Does the vendor offer audit logging for PHI access?
What subprocessors have access to PHI through this vendor?
Request Vendor Evaluation
Get a structured risk assessment for any vendor.
Request Benchmark Report
Compare vendors across your full stack.
Book Governance Assessment
Talk to a VNDRIQ governance specialist.